Genetic risk factors for Alzheimer's disease

Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers

Volumn , Issue , 2014, Pages 49-64

  Combarros, Onofre ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Alzheimer's disease; Epistasis; Genome wide association study meta analysis; Risk genes; Whole exome sequencing

Indexed keywords

EID: 84929700917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-6380-0_4     Document Type: Chapter

References (53)

1. Ertekin-Taner N. Genetics of Alzheimer disease in the pre- And post-GWAS era. Alzheimers Res Ther. 2010;2:3.
2. Bertram L. Alzheimer's genetics in the GWAS era: A continuing story of 'replications and refutations'. Curr Neurol Neurosci Rep. 2011;11:246-53.
3. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006296.
4. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013;12:92-104.
5. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168-74.
6. Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, et al. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset alzheimer's disease. J Alzheimers Dis. 2012;28:377-87.
7. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-81.
8. Bertram L, Tanzi RE. The genetics of Alzheimer's disease. In: Teplow D, editor. Progress in molecular biology and translational science, vol. 107. Burlington: Academic; 2012. p. 79-100.
9. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Mol Psychiatry. 2011; 16:903-7.
10. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging. 2012;33:437-56.
11. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet. 2007;39:17-23.
12. International HapMap Consortium. A genome haplotype map of the human genome. Nature. 2005;437:1299-320.
13. International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-61.
14. Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 2012;124:305-23.
15. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-73.
16. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifi es variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088-93.
17. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifi es variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-9.
18. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome- wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303:1832-40.
19. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429-35.
20. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436-41. doi:10.1038/ng.2802.
21. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Metaanalysis of 74, 046 individuals identifi es 11 new susceptibility loci for Alzheimeŕs disease. Nat Genet. 2013;45:1452-8.
22. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, et al. Variants in the ATPbinding cassette transporter (ABCA7), apolipoprotein E ?4, and the risk of late-onset alzheimer disease in African Americans. JAMA. 2013;309:1483-92.
23. Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, et al. Initial assessment of the pathogenic mechanisms of the recently identifi ed Alzheimer risk loci. Ann Hum Genet. 2013;77:85-105.
24. Manolio TA. Genome wide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.
25. Ertekin-Taner N, De Jager PL, Yu L, Bennett DA. Alternative approaches in gene discovery and characterization in Alzheimer's disease. Curr Genet Med Rep. 2013;1:39-51.
26. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics. 2011;187:367-83.
27. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, et al. Novel late-onset alzheimer disease loci variants associate with brain gene expression. Neurology. 2012;79:221-8.
28. Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol. 2011;37:353-7.
29. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631-43.
30. Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry. 2013;18:1225-34. doi:10.1038/mp.2013.1.
31. Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor CALM/PICALM is associated with neurofi brillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathol. 2013;125:861-78.
32. Rodríguez-Rodríguez E, Sánchez-Juan P, Vázquez-Higuera JL, Mateo I, Pozueta A, Berciano J, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm. 2013;120:807-12.
33. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: A meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:1149-56.
34. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One. 2011;6:e15918.
35. Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, et al. Genetic loci associated with Alzheimer's disease and cerebrospinal fl uid biomarkers in a Finnish case-control cohort. PLoS One. 2013;8:e59676.
36. Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI). Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67:677-85.
37. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747-53.
38. Zhu Q, Ge D, Maia JM, Zhu M, Petrovski S, Dickson SP, et al. A genome-wide comparison of the functional properties of rare and common genetic variants in humans. Am J Hum Genet. 2011;88:458-68.
39. Guerreiro RJ, Lohmann E, Brás JM, Gibbs JR, Rohrer JD, Gurunlian N, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78-84.
40. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Alzheimer Genetic Analysis Group, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013; 368:117-27.
41. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368: 107-16.
42. Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimer's disease. N Engl J Med. 2013;368:182-4.
43. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96-9.
44. Seng Ting SK, Chong MS, Kandiah N, Hameed S, Tan L, Au WL, et al. Absence of A673T amyloid-β precursor protein variant in Alzheimer's disease and other neurological diseases. Neurobiol Aging. 2013;34:2441e7-8.
45. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTDspectrum and Alzheimer's diseases. Hum Mol Genet. 2012;21:3500-12.
46. Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, et al. Genomewide haplotype association study identifi es the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry. 2013;18:461-70.
47. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U S A. 2012;109:1193-8.
48. Combarros O, van Duijn CM, Hammond N, Belbin O, Arias-Vásquez A, Cortina-Borja M, et al. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. J Neuroinfl ammation. 2009;6:22.
49. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer's disease. Neurobiol Aging. 2009;30:1333-49.
50. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: A statistic to measure interactions in complex diseases. BMC Res Notes. 2009;2:105.
51. Medway C, Combarros O, Cortina-Borja M, Butler HT, Ibrahim-Verbaas CA, de Bruijn RF, et al. The sex-specifi c associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. Eur J Hum Genet. 2014;22(2):216-20. doi:10.1038/ejhg.2013.116.
52. Lehmann DJ, Schuur M, Warden DR, Hammond N, Belbin O, Kölsch H, et al. Transferrin and HFE genes interact in Alzheimer's disease risk: The Epistasis Project. Neurobiol Aging. 2012;33:202.e1-13.
53. Bullock JM, Medway C, Cortina-Borja M, Turton JC, Prince JA, Ibrahim-Verbaas CA, et al. Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. Neurobiol Aging. 2013;34:1309.e1-e7.